Geographical variation in hospitalization for psychosis associated with cannabis use and cannabis legalization in the United States

2022 ◽  
pp. 114387
Author(s):  
Lauren V. Moran ◽  
Erica S. Tsang ◽  
Dost Ongur ◽  
John Hsu ◽  
May Y. Choi
Addiction ◽  
2018 ◽  
Vol 114 (4) ◽  
pp. 698-707 ◽  
Author(s):  
Beth Han ◽  
Wilson M. Compton ◽  
Carlos Blanco ◽  
Christopher M. Jones

2018 ◽  
Vol 79 (3) ◽  
pp. 423-431 ◽  
Author(s):  
Pia M. Mauro ◽  
Hannah Carliner ◽  
Qiana L. Brown ◽  
Deborah S. Hasin ◽  
Dvora Shmulewitz ◽  
...  

Author(s):  
Jarratt Pytell ◽  
Darius A. Rastegar

Tetrahydrocannabinol (THC) is the main psychoactive agent in the leaves of cannabis (marijuana) plants. Many synthetic cannabinoids have been recently developed. Cannabis is the most commonly used illicit drug in the United States; almost 20 million Americans currently consume cannabis. People who use cannabis may experience relaxation, euphoria, and mild hallucinogenic effects. Some may experience nausea and vomiting after use. Synthetic cannabinoids have been associated with more serious complications. Cessation after regular use may result in drug craving, insomnia, anorexia, and restlessness. Metabolites of THC can be detected in the urine up to 1 month after last use; some medications can cause false-positive tests. Serious medical complications of cannabis use are uncommon; the most concerning are neuropsychological problems among adolescent users and acute cognitive and motor impairment. Synthetic cannabinoid use is associated with significant neuropsychological effects. Psychosocial modalities appear to help those who wish to stop or reduce use. There are no medications that have been shown to be effective.


Author(s):  
Andrea H Weinberger ◽  
Jiaqi Zhu ◽  
Joun Lee ◽  
Shu Xu ◽  
Renee D Goodwin

Abstract Introduction Cigarette use is declining among youth in the United States, whereas cannabis use and e-cigarette use are increasing. Cannabis use has been linked with increased uptake and persistence of cigarette smoking among adults. The goal of this study was to examine whether cannabis use is associated with the prevalence and incidence of cigarette, e-cigarette, and dual product use among U.S. youth. Methods Data included U.S. youth ages 12–17 from two waves of the Population Assessment of Tobacco and Health (PATH) Study (Wave 1 youth, n = 13 651; Wave 1 tobacco-naive youth, n = 10 081). Weighted logistic regression models were used to examine the association between Wave 1 cannabis use and (1) Wave 1 prevalence of cigarette/e-cigarette use among Wave 1 youth and (2) Wave 2 incidence of cigarette/e-cigarette use among Wave 1 tobacco-naive youth. Analyses were run unadjusted and adjusted for demographics and internalizing/externalizing problem symptoms. Results Wave 1 cigarette and e-cigarette use were significantly more common among youth who used versus did not use cannabis. Among Wave 1 tobacco-naive youth, Wave 1 cannabis use was associated with significantly increased incidence of cigarette and e-cigarette use by Wave 2. Conclusions Youth who use cannabis are more likely to report cigarette and e-cigarette use, and cannabis use is associated with increased risk of initiation of cigarette and e-cigarette use over 1 year. Continued success in tobacco control—specifically toward reducing smoking among adolescents—may require focusing on cannabis, e-cigarette, and cigarette use in public health education, outreach, and intervention efforts. Implications These data extend our knowledge of cigarette and e-cigarette use among youth by showing that cannabis use is associated with increased prevalence and incidence of cigarette and e-cigarette use among youth, relative to youth who do not use cannabis. The increasing popularity of cannabis use among youth and diminished perceptions of risk, coupled with the strong link between cannabis use and tobacco use, may have unintended consequences for cigarette control efforts among youth.


1981 ◽  
Vol 59 (9) ◽  
pp. 1836-1846 ◽  
Author(s):  
Murray J. Kennedy

Previous experimental and field studies have shown that variations within the genus Haematoloechus may result from differences in age and degree of maturity, extent of crowding, species of host, and other factors.Based on these observations, only 6 of the 15 previously known species from Canada and the United States are considered valid. The valid species and their synonyms are as follows: Haematoloechus longiplexus Stafford, 1902; H. breviplexus Stafford, 1902; H. varioplexus Stafford, 1902 (= H. parviplexus, = H. buttensis, = H. similiplexus, = H. floedae, and H. uniplexus); H. kernensis Ingles, 1932 (= H. tumidus); H. medioplexus Stafford, 1902; and H. complexus (Seely, 1906) (= H. coloradensis, = H. confusus, = H. oxyorchis).The existence of three species groups is hypothesized. Haematoloechus longiplexus and H. breviplexus constitute one group, characterized by little geographical variation and a narrow host range. They are typically parasites of Rana catesbeiana and R. clamitans. Haematoloechus varioplexus and H. kernensis constitute the second group. These species have a wider host range and greater variation in characters purported to be specific differences. The third group includes those lung flukes which do not contain extracaecal loops (H. medioplexus and H. complexus). Of these, only H. medioplexus had little geographical variation and was found to occur in a single frog host.


2020 ◽  
Vol 209 ◽  
pp. 107894 ◽  
Author(s):  
Andrea H. Weinberger ◽  
Jiaqi Zhu ◽  
Joun Lee ◽  
Elle Anastasiou ◽  
Jan Copeland ◽  
...  

JAMA ◽  
2019 ◽  
Vol 322 (2) ◽  
pp. 167 ◽  
Author(s):  
Nora D. Volkow ◽  
Beth Han ◽  
Wilson M. Compton ◽  
Elinore F. McCance-Katz

Sign in / Sign up

Export Citation Format

Share Document